Johnson & Johnson is renovating a facility in the US to make anti-cancer CAR-T candidate LCAR-B38M licensed from Legend Biotech last year. In December 2017, J&J subsidiary Janssen Biotech, Inc., entered into the chimeric antigen receptor (CAR) T-cell space through a US$350 million (€304 million) collaboration and licensing deal with Chinese firm Legend Biotech. Legend’s oncology candidate, LCAR-B38M, targets the B-cell maturation antigen (BCMA) and is under review in China. At the Goldman Sachs Annual Global Healthcare Conference earlier this…